Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Shares Issued (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Shares Issued for 7 consecutive years, with $12000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Issued changed N/A year-over-year to $12000.0, compared with a TTM value of $150000.0 through Dec 2025, changed N/A, and an annual FY2025 reading of $150000.0, changed N/A over the prior year.
  • Shares Issued was $12000.0 for Q4 2025 at Keros Therapeutics, down from $117000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $107.3 million in Q1 2023 and bottomed at -$105.2 million in Q2 2023.
  • Average Shares Issued over 5 years is $268941.2, with a median of $117000.0 recorded in 2025.
  • The sharpest move saw Shares Issued soared 1576.19% in 2022, then crashed 17067.42% in 2023.
  • Year by year, Shares Issued stood at $379000.0 in 2021, then crashed by 15234.3% to -$57.4 million in 2022, then soared by 101.4% to $804000.0 in 2023, then tumbled by 1180.6% to -$8.7 million in 2024, then skyrocketed by 100.14% to $12000.0 in 2025.
  • Business Quant data shows Shares Issued for KROS at $12000.0 in Q4 2025, $117000.0 in Q3 2025, and $17000.0 in Q2 2025.